Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Nicolas Mounier, Matthias Karrasch et al.|Journal of Clinical Oncology|2016Cited by 121
ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.Patrice Carde, Nicolas Mounier, Matthias Karrasch et al.|Journal of Clinical Oncology|2012Cited by 50
CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)Norbert Schmitz, Michael Pfreundschuh, Mathias Haenel et al.|Blood|2010Cited by 6